Care Coordination for Mosunetuzumab Therapy in Patients With Follicular Lymphoma in Community Practices: Learnings From the MorningSun Study Investigators
ABSTRACT Background Preliminary data from the MorningSun study have demonstrated that outpatient subcutaneous mosunetuzumab can be safely administered. Aims This publication describes how community centers in the MorningSun phase 2 study of outpatient subcutaneous mosunetuzumab in B‐cell non‐Hodgkin...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.70936 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850127883623727104 |
|---|---|
| author | Tara Graff Ian Flinn Jeff P. Sharman Steven Liu Bertrand M. Anz Mitul Gandhi Ayed Ayed Richard Zuniga Abdul Hai Mansoor Lourenia M. Cassoli Mei Wu Prachi Jani Juliana M. L. Biondo Tony Lin John M. Burke |
| author_facet | Tara Graff Ian Flinn Jeff P. Sharman Steven Liu Bertrand M. Anz Mitul Gandhi Ayed Ayed Richard Zuniga Abdul Hai Mansoor Lourenia M. Cassoli Mei Wu Prachi Jani Juliana M. L. Biondo Tony Lin John M. Burke |
| author_sort | Tara Graff |
| collection | DOAJ |
| description | ABSTRACT Background Preliminary data from the MorningSun study have demonstrated that outpatient subcutaneous mosunetuzumab can be safely administered. Aims This publication describes how community centers in the MorningSun phase 2 study of outpatient subcutaneous mosunetuzumab in B‐cell non‐Hodgkin lymphomas prepared workflow and logistics (staff coordination, practice networks, and patient support) to monitor patients for cytokine release syndrome (CRS) and other toxicities. Materials and Methods Ten investigators at US community practice study sites (one rural, seven urban, and two rural/urban) were interviewed between January 12 and February 22, 2024. Interview transcripts were analyzed qualitatively to identify key themes. Results Prior to the study, 7/10 had limited/no experience administering bispecific antibodies for lymphoma. Regarding preparation before treatment, staff education was the most frequent need (7/10). All sites provided in‐service training for staff involved with treatment administration. Most respondents (6/10) had multidisciplinary plans and agreed these eased logistical concerns. Out of hours, patients either called the triage team, a dedicated on‐call number, the physician, or the emergency department. Most practices had preexisting relationships with hospitals for CRS management. All practices established methods for outpatient CRS monitoring; patient education and caregivers played important roles, and all respondents encouraged patients to use self‐monitoring devices. Each community practice had different workflow and logistics based on their setting and infrastructure. Conclusion Community practices can leverage other sites' experiences and adopt an individualized approach to implementing bispecific antibodies safely and efficiently. Designating a physician champion could provide a local resource to address staff questions and concerns. |
| format | Article |
| id | doaj-art-42068d4baa684c7ea28e30f71d670aa2 |
| institution | OA Journals |
| issn | 2045-7634 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-42068d4baa684c7ea28e30f71d670aa22025-08-20T02:33:32ZengWileyCancer Medicine2045-76342025-06-011411n/an/a10.1002/cam4.70936Care Coordination for Mosunetuzumab Therapy in Patients With Follicular Lymphoma in Community Practices: Learnings From the MorningSun Study InvestigatorsTara Graff0Ian Flinn1Jeff P. Sharman2Steven Liu3Bertrand M. Anz4Mitul Gandhi5Ayed Ayed6Richard Zuniga7Abdul Hai Mansoor8Lourenia M. Cassoli9Mei Wu10Prachi Jani11Juliana M. L. Biondo12Tony Lin13John M. Burke14Mission Cancer and Blood Des Moines Iowa USATennessee Oncology/OneOncology Nashville Tennessee USAWillamette Valley Cancer Institute Eugene Oregon USAAlaska Oncology & Hematology LLC Anchorage Alabama USATennessee Oncology/OneOncology Chattanooga Tennessee USAVirginia Cancer Specialists Gainesville Virginia USACancer Specialists of North Florida Jacksonville Florida USANew York Cancer & Blood Specialists Port Jefferson New York USAKaiser Permanente Portland Oregon USAGenentech, Inc. South San Francisco California USAGenentech, Inc. South San Francisco California USAGenentech, Inc. South San Francisco California USAGenentech, Inc. South San Francisco California USAGenentech, Inc. South San Francisco California USARocky Mountain Cancer Centers Aurora Colorado USAABSTRACT Background Preliminary data from the MorningSun study have demonstrated that outpatient subcutaneous mosunetuzumab can be safely administered. Aims This publication describes how community centers in the MorningSun phase 2 study of outpatient subcutaneous mosunetuzumab in B‐cell non‐Hodgkin lymphomas prepared workflow and logistics (staff coordination, practice networks, and patient support) to monitor patients for cytokine release syndrome (CRS) and other toxicities. Materials and Methods Ten investigators at US community practice study sites (one rural, seven urban, and two rural/urban) were interviewed between January 12 and February 22, 2024. Interview transcripts were analyzed qualitatively to identify key themes. Results Prior to the study, 7/10 had limited/no experience administering bispecific antibodies for lymphoma. Regarding preparation before treatment, staff education was the most frequent need (7/10). All sites provided in‐service training for staff involved with treatment administration. Most respondents (6/10) had multidisciplinary plans and agreed these eased logistical concerns. Out of hours, patients either called the triage team, a dedicated on‐call number, the physician, or the emergency department. Most practices had preexisting relationships with hospitals for CRS management. All practices established methods for outpatient CRS monitoring; patient education and caregivers played important roles, and all respondents encouraged patients to use self‐monitoring devices. Each community practice had different workflow and logistics based on their setting and infrastructure. Conclusion Community practices can leverage other sites' experiences and adopt an individualized approach to implementing bispecific antibodies safely and efficiently. Designating a physician champion could provide a local resource to address staff questions and concerns.https://doi.org/10.1002/cam4.70936best practicebispecific antibodiescare coordinationcommunity practiceoutpatient therapy |
| spellingShingle | Tara Graff Ian Flinn Jeff P. Sharman Steven Liu Bertrand M. Anz Mitul Gandhi Ayed Ayed Richard Zuniga Abdul Hai Mansoor Lourenia M. Cassoli Mei Wu Prachi Jani Juliana M. L. Biondo Tony Lin John M. Burke Care Coordination for Mosunetuzumab Therapy in Patients With Follicular Lymphoma in Community Practices: Learnings From the MorningSun Study Investigators Cancer Medicine best practice bispecific antibodies care coordination community practice outpatient therapy |
| title | Care Coordination for Mosunetuzumab Therapy in Patients With Follicular Lymphoma in Community Practices: Learnings From the MorningSun Study Investigators |
| title_full | Care Coordination for Mosunetuzumab Therapy in Patients With Follicular Lymphoma in Community Practices: Learnings From the MorningSun Study Investigators |
| title_fullStr | Care Coordination for Mosunetuzumab Therapy in Patients With Follicular Lymphoma in Community Practices: Learnings From the MorningSun Study Investigators |
| title_full_unstemmed | Care Coordination for Mosunetuzumab Therapy in Patients With Follicular Lymphoma in Community Practices: Learnings From the MorningSun Study Investigators |
| title_short | Care Coordination for Mosunetuzumab Therapy in Patients With Follicular Lymphoma in Community Practices: Learnings From the MorningSun Study Investigators |
| title_sort | care coordination for mosunetuzumab therapy in patients with follicular lymphoma in community practices learnings from the morningsun study investigators |
| topic | best practice bispecific antibodies care coordination community practice outpatient therapy |
| url | https://doi.org/10.1002/cam4.70936 |
| work_keys_str_mv | AT taragraff carecoordinationformosunetuzumabtherapyinpatientswithfollicularlymphomaincommunitypracticeslearningsfromthemorningsunstudyinvestigators AT ianflinn carecoordinationformosunetuzumabtherapyinpatientswithfollicularlymphomaincommunitypracticeslearningsfromthemorningsunstudyinvestigators AT jeffpsharman carecoordinationformosunetuzumabtherapyinpatientswithfollicularlymphomaincommunitypracticeslearningsfromthemorningsunstudyinvestigators AT stevenliu carecoordinationformosunetuzumabtherapyinpatientswithfollicularlymphomaincommunitypracticeslearningsfromthemorningsunstudyinvestigators AT bertrandmanz carecoordinationformosunetuzumabtherapyinpatientswithfollicularlymphomaincommunitypracticeslearningsfromthemorningsunstudyinvestigators AT mitulgandhi carecoordinationformosunetuzumabtherapyinpatientswithfollicularlymphomaincommunitypracticeslearningsfromthemorningsunstudyinvestigators AT ayedayed carecoordinationformosunetuzumabtherapyinpatientswithfollicularlymphomaincommunitypracticeslearningsfromthemorningsunstudyinvestigators AT richardzuniga carecoordinationformosunetuzumabtherapyinpatientswithfollicularlymphomaincommunitypracticeslearningsfromthemorningsunstudyinvestigators AT abdulhaimansoor carecoordinationformosunetuzumabtherapyinpatientswithfollicularlymphomaincommunitypracticeslearningsfromthemorningsunstudyinvestigators AT loureniamcassoli carecoordinationformosunetuzumabtherapyinpatientswithfollicularlymphomaincommunitypracticeslearningsfromthemorningsunstudyinvestigators AT meiwu carecoordinationformosunetuzumabtherapyinpatientswithfollicularlymphomaincommunitypracticeslearningsfromthemorningsunstudyinvestigators AT prachijani carecoordinationformosunetuzumabtherapyinpatientswithfollicularlymphomaincommunitypracticeslearningsfromthemorningsunstudyinvestigators AT julianamlbiondo carecoordinationformosunetuzumabtherapyinpatientswithfollicularlymphomaincommunitypracticeslearningsfromthemorningsunstudyinvestigators AT tonylin carecoordinationformosunetuzumabtherapyinpatientswithfollicularlymphomaincommunitypracticeslearningsfromthemorningsunstudyinvestigators AT johnmburke carecoordinationformosunetuzumabtherapyinpatientswithfollicularlymphomaincommunitypracticeslearningsfromthemorningsunstudyinvestigators |